JPWO2019203255A1 - 再構成癌組織を用いた薬剤評価方法 - Google Patents

再構成癌組織を用いた薬剤評価方法 Download PDF

Info

Publication number
JPWO2019203255A1
JPWO2019203255A1 JP2020514407A JP2020514407A JPWO2019203255A1 JP WO2019203255 A1 JPWO2019203255 A1 JP WO2019203255A1 JP 2020514407 A JP2020514407 A JP 2020514407A JP 2020514407 A JP2020514407 A JP 2020514407A JP WO2019203255 A1 JPWO2019203255 A1 JP WO2019203255A1
Authority
JP
Japan
Prior art keywords
cancer
cells
emt
administration
anticancer drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020514407A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019203255A5 (https=
Inventor
英樹 谷口
英樹 谷口
圭輔 関根
圭輔 関根
康晴 上野
康晴 上野
諒 奥田
諒 奥田
聡一郎 森永
聡一郎 森永
洋平 宮城
洋平 宮城
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kanagawa Prefectural Hospital Organization
Yokohama City University
Original Assignee
Kanagawa Prefectural Hospital Organization
Yokohama City University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kanagawa Prefectural Hospital Organization, Yokohama City University filed Critical Kanagawa Prefectural Hospital Organization
Publication of JPWO2019203255A1 publication Critical patent/JPWO2019203255A1/ja
Publication of JPWO2019203255A5 publication Critical patent/JPWO2019203255A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C12Q1/6874—Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020514407A 2018-04-19 2019-04-17 再構成癌組織を用いた薬剤評価方法 Pending JPWO2019203255A1 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018080585 2018-04-19
JP2018080585 2018-04-19
PCT/JP2019/016421 WO2019203255A1 (ja) 2018-04-19 2019-04-17 再構成癌組織を用いた薬剤評価方法

Publications (2)

Publication Number Publication Date
JPWO2019203255A1 true JPWO2019203255A1 (ja) 2021-06-10
JPWO2019203255A5 JPWO2019203255A5 (https=) 2022-03-02

Family

ID=68238962

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020514407A Pending JPWO2019203255A1 (ja) 2018-04-19 2019-04-17 再構成癌組織を用いた薬剤評価方法

Country Status (2)

Country Link
JP (1) JPWO2019203255A1 (https=)
WO (1) WO2019203255A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7702110B2 (ja) * 2020-04-28 2025-07-03 国立大学法人高知大学 ヒト膵癌オルガノイドを用いたマウスモデルの樹立
US20220276225A1 (en) * 2020-06-25 2022-09-01 Next & Bio Inc. Method for providing information necessary for diagnosing cancer patient's resistance to anti-cancer agent and/or radiation
EP4253516A3 (en) 2020-06-25 2023-12-06 Next & Bio Inc. Method for mass proliferation of stem cells without using hydrogel
US12606783B2 (en) 2020-06-25 2026-04-21 Next & Bio Inc. Well plate and 3D culture plate comprising the same
KR102746473B1 (ko) 2021-07-09 2024-12-26 주식회사 넥스트앤바이오 가상 오가노이드를 이용한 촬영 이미지 데이터 생성 방법
KR102746470B1 (ko) 2021-07-09 2024-12-26 주식회사 넥스트앤바이오 가상 오가노이드 생성 방법
WO2023238939A1 (ja) * 2022-06-09 2023-12-14 慶應義塾 癌の再燃若しくは再発の予防剤又は治療剤及びそのスクリーニング方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015153997A2 (en) * 2014-04-04 2015-10-08 Oncomed Pharmaceuticals, Inc. Notch3 antibodies and uses thereof
WO2016089208A2 (en) * 2014-12-04 2016-06-09 Stichting Maastricht Radiation Oncology "Maastro-Clinic" Sulfonamide, sulfamate and sulfamide derivatives of anti-cancer agents
JP2016520289A (ja) * 2013-03-15 2016-07-14 オンコメッド ファーマシューティカルズ インコーポレイテッド 膵臓癌の治療方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016520289A (ja) * 2013-03-15 2016-07-14 オンコメッド ファーマシューティカルズ インコーポレイテッド 膵臓癌の治療方法
WO2015153997A2 (en) * 2014-04-04 2015-10-08 Oncomed Pharmaceuticals, Inc. Notch3 antibodies and uses thereof
WO2016089208A2 (en) * 2014-12-04 2016-06-09 Stichting Maastricht Radiation Oncology "Maastro-Clinic" Sulfonamide, sulfamate and sulfamide derivatives of anti-cancer agents

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BRITISH JOURNAL OF CANCER, vol. 108, JPN6019021353, 14 March 2013 (2013-03-14), pages 1488 - 1494, ISSN: 0005115713 *
CANCER RESEARCH, vol. 69, JPN6019021354, 10 March 2009 (2009-03-10), pages 2400 - 2407, ISSN: 0005115714 *
CANCER TREATMENT REVIEWS, vol. 55, JPN6019021352, 2017, pages 36 - 45, ISSN: 0004973777 *
MEDICAL ONCOLOGY, vol. 27, JPN6019021356, 9 October 2009 (2009-10-09), pages 1017 - 1022, ISSN: 0004973779 *
NATURE, vol. 499, JPN6020022734, 3 July 2013 (2013-07-03), pages 481 - 484, ISSN: 0004973782 *
ONCOTARGETS AND THERAPY, vol. 6, JPN6019021355, 2013, pages 1249 - 1259, ISSN: 0004973778 *
公益財団法人日本膵臓病研究財団 第23回研究報告書 (2015年度), vol. 23, JPN6020022732, 20 December 2016 (2016-12-20), pages 131 - 135, ISSN: 0004973780 *
奥田諒 ほか: "[2P-0879] 腫瘍微小環境を有する患者由来ヒト膵癌オルガノイドの創出", 2017年度生命科学系学会合同年次大会 [ONLINE], JPN6020022730, 15 November 2017 (2017-11-15), ISSN: 0005115711 *
奥田諒 ほか: "[3AS13-7(3P-0750)] 腫瘍微小環境を模倣するヒト膵癌オルガノイドの創出", 第39回日本分子生物学会年会 [ONLINE], JPN6020022731, 16 November 2016 (2016-11-16), ISSN: 0005115712 *
濱中香織 ほか: "P-1236 ヒト膵癌オルガノイドを用いた新規薬剤評価系の構築", 第74回日本癌学会学術総会 [ONLINE], JPN6020022733, 2015, ISSN: 0004973781 *

Also Published As

Publication number Publication date
WO2019203255A1 (ja) 2019-10-24

Similar Documents

Publication Publication Date Title
JPWO2019203255A1 (ja) 再構成癌組織を用いた薬剤評価方法
Yadav et al. Cancer stem cells: acquisition, characteristics, therapeutic implications, targeting strategies and future prospects
Comoglio et al. Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy
Lonardo et al. Pancreatic stellate cells form a niche for cancer stem cells and promote their self-renewal and invasiveness
Lin et al. Impact of the hypoxic tumor microenvironment on the regulation of cancer stem cell characteristics
Huang et al. Recent advances in understanding cancer-associated fibroblasts in pancreatic cancer
Teodorczyk et al. Notching on cancer’s door: Notch signaling in brain tumors
Xiao et al. The lymphovascular embolus of inflammatory breast cancer expresses a stem cell-like phenotype
Kahlert et al. Activation of canonical WNT/β-catenin signaling enhances in vitro motility of glioblastoma cells by activation of ZEB1 and other activators of epithelial-to-mesenchymal transition
Choi et al. Identification of brain tumour initiating cells using the stem cell marker aldehyde dehydrogenase
JP6960140B2 (ja) 腫瘍組織再現法
Mukaida et al. Fibroblasts, an inconspicuous but essential player in colon cancer development and progression
US8765797B2 (en) TG2 inhibitors and uses thereof
Chen et al. Mechanisms of breast cancer metastasis: the role of extracellular matrix
Yin et al. The role of glioma stem cells in glioma tumorigenesis
Mahmoodi et al. PlGF knockdown decreases tumorigenicity and stemness properties of spheroid body cells derived from gastric cancer cells
Jung et al. Decursin inhibits vasculogenesis in early tumor progression by suppression of endothelial progenitor cell differentiation and function
Mu et al. The roles of cancer stem cells and therapeutic implications in melanoma
Wang et al. Cancer stem cell niche in colorectal cancer and targeted therapies
Dittmar et al. Role of cancer stem cells in cancer biology and therapy
Ping et al. Cancer stem cells switch on tumor neovascularization
JPWO2019203254A1 (ja) 上皮間葉転換関連分子を用いた癌評価法
Masciale et al. Cancer stem cells and their microenvironment
Fujiwara et al. Cancer stem cells of sarcoma
Sinnberg et al. Embryonic bone morphogenetic protein and nodal induce invasion in melanocytes and melanoma cells

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20200828

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200828

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220221

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230125

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230726